GenCurix Obtains Patent for Prognosis Prediction Method in Breast Cancer Patients
[Asia Economy Reporter Minwoo Lee] GenCurix announced on the 6th that it has obtained a U.S. patent titled "Methods for predicting risk of recurrence of breast cancer patients."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- [Breaking] President Lee: "South Korea and Japan to Further Expand Supply Chain Cooperation"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "This patent involves diagnosing breast cancer patients who require treatment by measuring the messenger RNA (mRNA) expression levels of proliferation-related gene clusters and immune-related genes from biological samples of breast cancer patients, where an increase in the standardized expression combination of proliferation-related gene clusters or a decrease in the expression levels of immune-related genes indicates the need for treatment. This patent, already registered domestically, has now been registered in the U.S., and applications have also been completed in China, Europe, and Japan."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
